Index

A. & E. Plastik Pak v. Monsanto 365
Abbreviated New Drug Applications (ANDAs) 467–8, 469, 472, 481–2, 488
Abramowicz, M. 144, 145–6
Abrams, H.B. 323
absolute liability rules 185–6
absolute secrecy, lack of 160
access
environmental law 456–8
protecting a commons 238–40
and trade secrecy in expression 310–30
accountability 406, 407
search engines, secrecy and 384–92
see also transparency
active course of conduct 61
actual secrecy 57
actual use 166–7
Adidas 289
advertising, online 392–3
affirmative measures 61, 73
agency expertise 383–4, 392–8, 404
aggregation of data 487–8
Agreement on Trade-Related Aspects of Intellectual Property Law see TRIPS Agreement
agricultural traditional knowledge 510
Akerlof, G. 455
Albania 583
Allen, R.C. 203, 209, 213, 214
Alliance for Taxpayer Access 425–6
Amazon 403
ambit of protected subject matter 144, 145–7
American Bar Association, Patent, Trademark and Copyright (PTC) Section 554
American Intellectual Property Law Association (AIPLA) 105
American Law Institute 19, 20, 21, 22, 116, 553
American Tobacco Co. v. Werckmeister 306
Amoco Prod. Co. v. Laird 412, 413
Amunson, J.R. 395
analytical framework for antitrust and trade secrets 366–79, 380
application of general principles 372–9
monopoly firm conduct 375–9
price and territorial license restrictions 372–5
general principles 366–72
respect the bargain 371–2
trade secret distinctiveness 366–9
trade secrets' legal properties 369–71
ancillary restraints 347, 370
Andean countries 588
Anderman, S.D. 144
Anderson, C. 396
Anell Draft 550–51
Animal Welfare Act 426, 427
antitrust enforcement guidelines 338–9
antitrust law 332–80
analytical framework for antitrust and trade secrets 366–79, 380
antitrust treatment of trade secrets 339–66
current law 350–65
historical background 339–50
monopolies 335–6, 358–65, 375–9
restraints of trade 344–50, 350–58, 372–5
Aoki, K. 237–8
Apache help-line websites 208–9
appellate courts’ de novo reviews 296
Apple Computer 282
application costs 173–4
application programming interfaces (APIs) 378–9
apprenticeships 174

591

Rochelle C. Dreyfuss and Katherine J. Strandburg - 9780857933072
Downloaded from Elgar Online at 06/12/2019 07:33:46PM
via free access
appropriability 336
Argentina 573
Aronson v. Quick Point Pencil Co. 375
Arrow’s Information Paradox 127, 223
Article 39 of the TRIPS Agreement 141, 142, 186
Article 39(3) 516, 565–6, 568–82, 589
indigenous innovation 501–2, 510, 512, 513, 514–20, 521, 525, 534
negotiation history 539–52, 561, 564–5
drafting phase 541, 549–52
early phase 541–5
mid-term phase 541, 546–9
and the UTSA on which it is based 186, 537–9, 552–62
impact of pre-emption principles 563–5
limitations on the scope of U.S. trade secret law and 552–63
Associated Press (AP) 226–7
Attorney General 406
attorneys 83, 87, 98, 99
networks among like-minded 105–6
problems with the intellectual property bar 103–4
Austin, G.W. 303
Australia 400, 568
Pitjantjatjara People 511–13
Auto Channel, Inc. v. Speedvision Network, LLC 32, 36
automated decision systems 398–400
bad faith litigation 363–5
Baidu 385
Balboa Ins. Co. v. Trans Global Equities 308
ballpoint pens 189
bargain
antitrust law and trade secrets 368–9
lack of a disclosure bargain 371–2
respecting the bargain 371–2
copyright 306–7
Bartnicki v. Vopper 292–4
Basheer, S. 579
Basic Framework of GATT Provisions on Intellectual Property 542–4,
545, 561
Battelle, J. 385, 391
Behr, C. 455, 457
Ben-Atar, D.S. 164
benefit sharing agreements 526–8
Berkey Photo, Inc. v. Eastman Kodak, Inc. 358–60, 378
Berne Convention 303, 326–7, 503
bilateral cross-licenses 246, 255, 265
biodiversity 497
bioequivalence 467–8, 481
BioForge 235–8, 240, 263
biogenetic materials 526–8
Biological Open Source (BiOS) initiative 235–7, 263
BioMoby messaging standard 254
biotechnology
open 235–7, 246–66
rise of trade secrecy protection in 248–50
BioZulua database project 532, 533–4
Birrell, A. 323
Bisphenol A (BPA) 451, 452
black hat SEO 387–8, 389–91
Blackstone, W. 101
Blair, R.D. 159
blast furnaces 203, 209
Bodenhansen, G.H.C. 515–16
BondPro Corp. v. Siemens Power Gen, Inc. 59
Bone, R.G. 109, 121, 127–8, 131, 134, 146, 148, 415
Bonito Boats, Inc. v. Thunder Craft Boats, Inc. 339, 372
Boucicault v. Hart 303, 320
boundary conditions 237–40
Bounty bar 11
Boyle, J. 194
Bracha, O. 242
brand name pharmaceutical industry (Big Pharma) 575–6
Brandeis, L.D. 179–80
Braudel, F. 101
Bray, C. 382–3
Brazil 125, 156, 165, 537, 541
breach of confidence 31, 38, 41–2, 112, 133, 279–80, 287–8, 513
breach of contract 279–80, 287–8, 558–9
breach of loyalty 38, 41–2
Brenner, J.G. 8–9
breast cancer 451–2
breathalyzer machines 382, 423–5
Bridge Publications, Inc. v. Vien 524
Bridy, A. 402
Bristol v. Equitable Life Ass. Soc’y 50, 51
British Statute of Anne 320
Broadcast Music, Inc. v. Columbia Broad. Sys., Inc. 373
Brussels Draft 551
Bulgaria 583
Bunner, A. 274, 275, 277
Burbank Grease Services, LLC v. Sokolowski 34–5
Burk, D.L. 224, 244
Bush, G.W. 396
business advantage 227–9, 230–31
business-to-business confidentiality contracts 88
business relationships cases 38, 42–4, 114
Business Week 288–9
Cadbury 8, 9
Calabresi, G. 457–8
California 85, 92, 95, 135
State Bar 105–6
Cambodia 583
Canada 548, 561, 568
candy industry 3–17
Carbo Ceramics, Inc. v. Keefe 414
CARIFORUM Economic Partnership Agreement 588
Carrier, M. 399
Carter, S.L. 120
Cassiers, V. 249
Cava, A. 120–21
CBS, Inc. v. Davis 283–5, 286, 287, 295–6
CDN Inc. v. Capes 175–6
Cel-Tech Communications v. L.A. Cellular Tel. Co. 135
cellophane 353–4, 373–4, 375
censorship 285
center for Applications of Molecular Biology in International Agriculture (CAMBIA) 235, 263
Centers for Disease Control (CDC) 450
Cenveo Corp. v. Slater 35
ceremonies, sacred 223, 495, 511
Chally, J.R. 90
Charlie and the Chocolate Factory (Dahl) 3–8, 12, 15
chefs, French 238–9, 240
chemicals see environmental law
Chiappetta, V. 62–3
Chicago Board of Education v. Substance, Inc. 319, 320, 324
Chicago Lock Co. v. Fanberg 271–2, 276
children 450–51
Chile 582
China 582–3
chocolate 8–11
chocolat 9
Christus, D.N. 416
Chrysler v. Brown 477
Church of Scientology 523–4
Citizens Comm’n on Human Rights v. FDA 429
Citron, D.K. 383, 398, 399–400
civil conspiracy 40–41
clarity, lack of 99
Clayton Antitrust Act 356
clean hands doctrine 60–61
clearinghouses 247, 258–62, 265
ClearOne Comm., Inc. v. Chiang 96
clinical chemistry analysers 204
clinical trials data see test data exclusivity
CMI Inc. Intoxylizer 5000 machine 424–5
Coca-Cola 128, 130, 138, 222, 231, 232, 416
Coca-Cola Bottling Co. v. Coca-Cola Co. 416
Cohen v. Cowles Media Co. 287–8
COICA Statement on Intellectual Property Rights and Biodiversity 503
collaborative creativity 499
collaborative licensing strategies 246–66
collective action model for innovation incentives 216–18, 220
collective learning 213
collective ownership 503–6
Collins, T. 446
Colorado 87
commercial morality 120–21
commercial use 413–16
commercial value
Article 39 of the TRIPS Agreement 520, 521, 550–51, 556
environmental law 458–62
indigenous innovation 520–26
trade secrets and antitrust law 369–71
Commission on Intellectual Property, Innovation and Public Health (CIPIH) 577
common law 18, 21–2
displacing with the UTSA 33–44
problem of multiple regimes of confidentiality 77–108
see also torts
commons 190–92, 193, 194, 222–45
creating and protecting through secrecy 233–43
defining 225–7
misappropriation and commons governance 227–9, 231–3
preserving in a hyper-protectionist legal environment 195–8
reconstructed or positive 256
secret methods and constructing a commons 240–43
secrets as commons resources 235–7
seminowcs 191, 192–3, 194
trade secrecy as a feature of 227–33
communication, risk 456–8
communications protocols 378–9
communities, innovation 213, 214, 219–20, 236–7, 508–9
Compco Corp. v. Day-Brite Lighting, Inc. 135, 554
compensation 114, 578–81
monetary relief 24–5, 439
compensatory liability regime 197–200, 579
competition 262
anticompetitive effects of trade restraints 373
trade secrets and antitrust law 332–80
competitive harm 489–90
competitive intelligence gathering 113–14
competitive morality 519
compulsory licenses 586–8

Computer Associations International v. Altai, Inc. 308
computer hacking 421
computer language 177
Compuware case 309
concealment strategy 73, 75
concreteness of an idea 31–2
conduct-based liability rules 185, 187, 189–90, 193
see also liability rules
confidence, breach of 31, 38, 41–2, 112, 133, 279–80, 287–8, 513
confidential relationships 367
business relationships cases 38, 42–4, 114
‘implied’ 307–8
confidential treatment of data 467, 469, 473–80, 486
confidentiality contracts 43–4, 80, 88–91, 99, 107, 127, 162, 252
confidentiality torts 91–8, 99, 100, 108
consistency, lack of 99
consultants 170
Content Scramble System (CSS) 274–5, 294
counterfeit products 448–9
continuous use requirement 25–7, 30
contractarianism 66
contracts 264, 334
antitrust law and trade secrets 339–44
breach of contract 279–80, 287–8, 558–9
confidentiality contracts 43–4, 80, 88–91, 99, 107, 127, 162, 252
contract law and trade secret theory 118
contracting around trade secret law 137
implied-in-fact 30–31
implied-in-law 31, 32
public funded/sponsored research and 418, 425–8
contributory negligence 69–70, 136
Convention on Biological Diversity 497
Convention on the Protection and Promotion of the Diversity of Cultural Expressions 508
Convention for the Safeguarding of Intangible Cultural Heritage 508
Conyers, J. 397
copyright 18, 47, 68, 111, 122, 137, 236, 280–81
access and trade secrecy in expression 310–30
candy industry and 12–13
deposit requirement 301, 312–20, 329
disclosure 124
effect of a trade secret on 176–8
effect on a trade secret 175–6
impetus for secret copyrights 310–12
and incentives 152–3, 158–9, 166–7, 174–8, 202, 211–12
pre-emption 37–8, 301–2, 303–9
regime choice 336–8
trade secrets and the ‘philosophy’ of 299–331
Copyright Act 37, 44, 181
1909 version 302, 313–15
1976 version 300, 301–3, 315–18
Copyright Office 301, 310, 311–12, 313–19, 329
core business method 408
core developers 215
Cortés, H. 9
cosmetics 448–9
cost sharing compensation model 580
Cotter, T.F. 159
courts
absence of a centralized system 102
state courts see state courts
Cover, R.M. 403
Crane Helicopter Servs. v. U.S. 412–13
Creative Commons 260
credible commitment 262
credit checking systems, online 208
criminal penalties 114
Critical Infrastructure Information Act (CIIA) 436–7
Critical Mass Energy Project v. Nuclear Regulatory Comm’n 463
cross-licensing 246, 255, 265
cultural participation, right of 507–9
current employees 41–2
custodianship 502–10
customer lists 157
CVD v. Raytheon 338, 363–4
Daes, E.I. 503–4
Dahl, R. 8
Charlie and the Chocolate Factory 3–8, 12, 15
Dallas Cowboy Cheerleaders, Inc. v. Scoreboard Posters, Inc. 279
damages see compensation
data exclusivity see test data exclusivity
data sharing 491
database protection laws 195
database trusts 534
databases 530–32, 533–4, 535
DataMaster breathalyzer machine 423–4
de novo review 296
DeCSS 274, 275, 276, 278, 294
deculturization 506, 524–6
Defcon, Inc. v. Webb 28
deference 366–9
definition of a trade secret 25–8, 57, 77, 78, 227–9, 333–6, 407, 409–13
and commons resources 229–30
narrowing and transparency 438
TRIPS Agreement 546–9
UTSA 25–8, 57, 227–8, 250, 334, 414–15, 521
Del Madera Props. v. Rhodes & Gardner, Inc. 308
departing employees 79, 80, 114, 118
deposit requirement 301, 312–20, 329
DES 451
Desert Bar 10
design protection laws 194, 195
developing countries 148, 200, 546, 547, 571–2, 574, 584–5
Diamond Power Int’l, Inc. v. Davidson 96
diasporic ownership 506–9
Dicks v. Jensen 61
Diebold Election Systems 419–23
Digidyne Corp. v. Data General Corp. 357–8
Digital Millennium Copyright Act (DMCA) 177
digitized books 401
Dinca, R. 574, 579–80
disclosure 110, 251
clinical trials data 479–80, 482–5
accelerating the time of data disclosure 486–91
The law and theory of trade secrecy

copyright vs trade secrecy 330–31
environmental law 464
First Amendment and public disclosure 271
forced 155
intellectual property theory and incentives to disclose 123–8
trade secret law encouraging 148
disclosure bargain see bargain
dishonest practices 551, 552, 577
distinctiveness of trade secrets 366–9
Diversity Arrays Technology (DArT) 263
Doha Declaration 582, 587
dominant design 214
Dove candy bar 10
Dr. Miles Medical Co. v. John D. Park and Sons Co. 347–50
Draft Database Treaty 533
Dreyfuss, R. 255
drugs see pharmaceutical industry; test data exclusivity
due process issues 295–7
Duffy, J.F. 144
Dun & Bradstreet, Inc. v. Greenmoss Builders, Inc. 438
Dunkel Draft 552, 569
DuPont 453
cellophane case 353–4, 373–4, 375
Masland case 115–16, 132, 133, 280
duration of protection 571
analytical framework for antitrust and trade secrets 367, 374
infinite possible duration 416–17
injunctive relief, UTSA and the TRIPS Agreement 561–2
IP theory of trade secrets 138
limiting and transparency 438
regulatory exclusivity 481–2
trade secrets vs patents 168–9, 337
DVD Copy Control Association v. Bunner 167, 270, 274–9, 283–5, 294, 296
DVDs 177
dynamic innovation 144
E. Bement & Sons v. Nat'l Harrow Co. 348
E.I. duPont de Nemours Powder Co. v. Masland 52, 115–16, 132, 133, 280
eBay 401, 403
EC Guidelines 544–5
economic impact of data exclusivity 584–5
economic theories 64–5
economic value see commercial value
Edwards, A. 382–3
efficiency 373–5
Elcor Chem-Co. v. Agri-Sul, Inc. 89
Eldred v. Ashcroft 283, 307, 321
Electro-Craft Corp. v. Controlled Motion, Inc. 60–61
eligibility of subject matter 112
Ellsberg, D. 290–91
embedded Linux 206, 215–16
employee confidentiality contracts 88, 89, 91
employee training 86–7
employer-owned information 161–2
employers 91
endocrine disruptors 451
enforcement costs 63, 67–71
error costs 70–71
process costs 67–70
Enter. Leasing Co. v. Ehmke 48
environmental law 442–66
alternatives 464–6
knowledge problem in 446–55
expanding information deficits 449–50
pollution and information 446–9
small doses with large effects 450–52
weakened risk management 452–5
legal regime 455–64
access and communication 456–8
commercial secrecy 458–62
FOIA 443–4, 462–4
Environmental Protection Agency (EPA) 281–2, 443, 444, 453–4
Erie R. R. v. Tompkins 554
error costs 70–71
espionage 9, 11, 80
established, slow-growth businesses 87
ethics see morality/ethics
Europe 248–9
European Community (EC) 568, 569
EC Guidelines 544–5
FTAs 588
interpretation of TRIPS Agreement Article 39(3) 571
negotiation of TRIPS Agreement Article 39 542, 544–5, 548, 549–51
European Free Trade Association (EFTA) 580–81
European Microsoft case 360–62, 377
European Patent Convention (EPC) 144–5, 146, 147
European Union (EU)
Cosmetics Directive 449
Database Directive 533
REACH program 445–6
evidentiary benefits 59–60, 63
exclusivity 122, 155
environmental law 464–5
innovative know-how and exclusive rights 191, 192, 194, 195–8, 199
test data see test data exclusivity
exhaustion doctrine 371
exposure levels 450–52
expression, trade secrecy in 310–28
extraordinary circumstances 483–5, 486
facts 175
fair use 324–5
false allegations 515, 516
Fauchart, E. 238–9
federal courts 102
Federal Food, Drug and Cosmetic Act (1938) (FDCA) 473, 478
Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) 448, 464–5, 579, 581
Federal Rules of Civil Procedure (FRCP) 395
federal statutory right, absence of a 368
Federal Trade Commission (FTC) 360, 383, 392–3
federalization of trade secret law 106–8
Fellmeth, A. 578–9
Fenster, M. 434
fetuses 450–51
Finkel v. U.S. Dept of Labor 432
First Amendment 138, 391–2
defenses 269–98
direct misappropriators and 287–8
likelihood of increasing tensions with trade secrecy law 274–7
no categorical immunity for trade secret claims 277–85
other due process issues 295–7
rare use of 271–4
reconsidering trade secret claims and the prior restraints doctrine 286–95
third party recipients of newsworthy secrets 288–95
fixation, copyright and 312–13, 324–7
flawed data 107
flexibility 510–13, 515–16, 518, 535–6, 567
float glass technology 354–6, 365
FMC Corp. v. Varco Int’l, Inc. 131–2
Food and Agriculture Organization (FAO) 528
Panel of Eminent Experts on Ethics in Food and Agriculture 577–8, 586
Food and Drug Administration (FDA)
clinical trial data and new drug applications 467–91
impact of the Hatch-Waxman Act 480–86
origins of current administrative practice 473–80
Transparency Task Force 480, 483–4
Foray, D. 212–13
forced disclosure 155
Ford Motor Co. v. Lane 289–90
formulae/recipes, secret 9, 10, 11, 13, 178–9, 238–9, 343–50, 416
Foster v. Mountford 511–13, 523
Foundry Servs., Inc. v. Beneflux Corp. 352–3, 374

Rochelle C. Dreyfuss and Katherine J. Strandburg - 9780857933072
Downloaded from Elgar Online at 06/12/2019 07:33:46PM
via free access
The law and theory of trade secrecy

Fowle v. Park 343–4, 350, 373, 374
Frone, N. 205
Franke v. Wiltschek 55–6, 92–3, 132
fraud 39
free riding 117, 195–6, 218–19
pharmaceutical industry 469, 472, 482, 485
free speech defenses see First Amendment
free trade agreements (FTAs) 570, 580–81, 587–8, 589–90
Freedom of Information Act (FOIA) 406, 474–5, 577–8, 566
environmental law 443–4, 462–4
trade secrecy exception to 428–32
French chefs 238–9, 240
Frischmann, B.M. 226, 227, 241, 434
frivolous suits 70–71
FUDECI 532, 533
‘full reports’ of drug investigations 475–6, 479, 480–81, 482–3, 485, 488
Galanter, M. 104
game theory 74
gamespace 403
Garth v. Staktek Corp. 286–7
General Dynamics Corporation 430
General Public Licence (GPL) 205, 213, 263
general rule, and RSP requirement 70, 71–2, 73
generational innovation 499
see also indigenous innovation
Georgia 583
Germany 521
Ghidini, G. 145
Gilson, R.J. 164
GNU General Public License (GPL) 205, 213, 263
goals of trade secret law 101–2
gobstoppers 8
Gonzales v. Google, Inc. 395
Google 498
search engine results as a commons 240–43
governance, commons 227–9, 231–3
government and the private sector see private sector–government relationship
public funded/sponsored research 190–92, 418, 425–8, 491
regulation see regulation
test data exclusivity see test data exclusivity
use or disclosure and the First Amendment 281–2
see also public infrastructure
Graves, C.T. 35, 63
Grimmelmann, J. 387, 399
Guatemala 572
guilds 125
hacking, computer 421
Halavais, A. 385
Hamilton Mfg. Co. v. Tubbs Mfg. Co. 52
Harhoff, D. 206
‘Harry Potter’ books 179
Hartman v. John D. Park & Sons Co. 345
Hatch-Waxman Act 467–8, 469, 480–86, 488
Hauk Mfg. Co. v. Astec Industries, Inc. 89–90, 96
health care 384, 402
Heath candy bar 11
Helsinki Declaration 585
Henderson, W. 104
Henkel, J. 205–6, 215–16
Hershey 9–12, 15
Hertel, G. 214, 219
‘heterox’ reading of Article 39(3) 573–4
Hill, J.W. 66
Hirsch, S. 395
historical accident 101
Hoboken, City of 417
honest commercial practices 513, 514, 515–16
acts contrary to 551, 552, 577
honor 239
Hopi Indians 495, 506, 511, 525
House v. Commonwealth 424–5
House Judiciary Committee 319
Index 599

Howell, H.A. 302

_Hudson Hotels Corp. v. Choice Hotels Int’l_ 30
human dignity 507–9
human gene therapy 479–80
human rights 507–9
hybrid agreements 255, 265
hybrid legal regimes 191, 194, 195–8, 199
Hyde, A. 163
hydraulic fracturing (fracking) 447
hyper-protectionist legal environment 195–8

Iams Company 426–7
IBM 204
ideas
  copyright and 175, 176
  submission 29–33, 133
identical/similar information 166, 207–9
illegally intercepted telephone calls 292–4
Illinois 95
_Illinois Toolworks v. Independent Ink_ 335, 357
_Image Technical Servs., Inc. v. Eastman Kodak_ 375–6
‘implied’ confidential relationships 307–8
implied duty 113
implied-in-fact contract claims 30–31
implied-in-law contract 31, 32
_In the Matter of Intel Corp._ 360
_In re Bass_ 412
_inadvertence, legislative_ 303, 312–28, 330
incentives 64–5, 119, 152–82, 366–7
  among different intellectual property frameworks 165–81
  copyright and 152–3, 158–9, 166–7, 174–8, 202, 211–12
  created by trade secret law 159–63
to disclose 123–8
inherent secrecy incentives 155–63
intellectual property theory of trade secrets 122–3

  patenting and 122–3, 147–8, 152–3, 158–9, 166–7, 167–74, 181
positive incentives for open revealing 212–16
private-collective model for 202, 216–21
trade secret law vs no protection 154–65
trade secret law vs right to privacy 179–81
trademarks and 166–7, 178–9
independent development 73, 142, 166, 560–61
India 541, 546–7, 564, 588
test data protection 572–3
indigenous innovation 223, 495–536
  commercial value 520–26
  evolving concept of international trade secret protection 501–2
  ignored concept 498–501
  ownership issue 502–10
  practical problems in trade secret protection 526–9
  protection as unfair competition or property right 513–20
  secrecy as a flexible standard 510–13
  trade secrets and patents 530–34
  inert pesticide ingredients 448
  inevitable disclosure injunctions 85, 106
information see _knowledge/information_
information clearinghouse 259
information technology 204–5, 300–301, 418
  _see also_ Internet; software; websites
  infrastructure
  open 251–4
  public see public infrastructure
_Ingersoll-Rand Co. v. Ciavatta_ 100
injunctions 24, 114–15
  denying to improve transparency 439
  indigenous innovation 511, 512
  inevitable disclosure injunctions 85, 106
  with limiting terms 296
  in ordinary trade secret cases 286–7
  preliminary 283–5, 286–7, 296
tailed to respect First Amendment values 297
The law and theory of trade secrecy

UTSA, TRIPS Agreement and the duration of injunctive relief 561–2
innovation 100, 336, 498
dynamic 144
effects of secrecy on 472–3
EPC 144–5
generation of innovative know-how 185–200
incentives see incentives
indigenous see indigenous innovation
open see open innovation
protection of investment in 187–90
and the requirement of reasonable secrecy precautions 46–76
small-scale 194, 195–8, 198–200
innovation communities 213, 214, 219–20, 236–7, 508–9
innovativeness 336, 373–4
institutions 226–7, 233
trusted 383–4, 392–8, 466
Intel 360
intellectual property (IP) 202, 244, 262, 334
environmental law and 459–60
international agreements 539–40
see also TRIPS Agreement
regime choice 336–9
regimes and incentives to innovate 152–4, 165–81
similarities and dissimilarities of trade secrets to 166–7
trade secrets as 109–39, 185–7
constructing an IP theory of trade secrets 121–31
implications for trade secret law 131–8
in Italy 140–51
see also copyright; patents; property rights; trademarks
intellectual property bar 103–4
intellectual property counseling 83
Intellectual Property Licensing Guidelines 332, 338–9, 351, 356–7
interests served by confidentiality regimes 82–3, 87, 91, 98, 98–9
interface information 376–9
interference with business relations 38, 42–4, 114
Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC) 496–7, 507
intermediary products 250
internal balances 371–2
International Covenant on Civil and Political Rights (ICCPR) 507–8
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 572, 575–6
International Technologies Consultants, Inc. v. Pilkington PLC 365
international trade secret protection 500–501
evolving concept 501–2
TRIPS Agreement see TRIPS Agreement
unfair competition or property right 513–20
International Treaty on Plant Genetic Resources for Food and Agriculture 200
Internet 225, 499
indigenous innovation and websites 530–32
 postings and the First Amendment defense 274–9
search engines see search engine rankings/results
intoxication-detection instruments 382, 423–5
Investigational New Drug applications (INDs) 474, 479
investment
over-investment in secrecy 124–6, 129
protection of investment in innovation 187–90
iron industry 203, 209
Iroquois 525
Italian Code of Industrial Property 140–51, 198, 248
critical assessment 143–9
economic drivers of the new regime 149–50
new regime 142–3
Index 601

J.T. Healey & Son, Inc. v James A. Murphy & Son, Inc. 55, 60
Jager, M. 115
Janke, T. 505–6
Japan 165, 521, 545
John D. Park & Sons Co. v. Hartman 345–7, 349–50
Johnson-Laird, A. 310
Joint Stock Soc’y v. UDV N. Am., Inc. 414
Jordan 582, 584–5
journalists 288–95
Junker v. Plummer 56
Kachina masks 525
Kamin v. Kuhnau 131
Kaplan, B. 323
Kelty, C.M. 397
Kentucky 36
Kentucky Fried Chicken Original Recipe 178
Keraplast Technologies 297
Kewanee Oil Co. v Bicron Corp. 122–3, 130, 230, 272–3, 305, 328, 335, 366, 563
Kirk, M. 558, 566
Kitch, E.W. 63, 143
Klandermans, B. 219
know-how 335
  natural semicommons of innovative know-how 185–200
tacit 169–70
knowledge/information
  knowledge/information commons see commons
  knowledge problem in environmental law 446–55
  sharing 155, 163–5
  substitute information 166, 207–9
  traditional see indigenous innovation
Kodak 358–9, 378
Koppel, N. 382–3
Korea, South 580–81
Kreiss, R.A. 177, 323
KSR Int’l Co. v. Teleflex, Inc. 196, 369
La Cellophane 353–4, 375
labor mobility 101, 163–4
Ladas, S.P. 188
Lakhan, K. 208–9
land 281
Landes, W.M. 153
Lanham Act 18, 44
law firms 174
law of ideas 29–30
law scholars 103, 104–5
Law School Aptitude Tests (LSATs) 300
lead time, natural 142, 189, 252
learning
  collective 213
  through practice 174
Lebanon 580
Leegin v. PSKS 351–2
legislation 106
  legislative inadvertence 303, 312–28, 330
Lemley, M.A. 143, 148, 195, 227, 248
Leon County, Florida 421
Lerner, J. 213, 408
Lester, G. 86
Levin, R.C. 211
Levine, D. 383, 393–4, 399
Levy, S. 388
liability rules 197
  absolute 185–6
  compensatory liability regime 197–200, 579
  conduct-based 185, 187, 189–90, 193
liability torts, strict 559–60
Library of Congress 124, 313–19, 401
library IT search software 204–5
licensing
  collaborative 240–66
  compulsory 586–8
  encouraged by trade secret law 64–5
  mass market licenses 274
Lim, K. 204
limited commons 237–8
limited ‘head start’ injunction 114–15
liquorice bootlaces 8
lithographic equipment 204
Lithuania 583
litigation 100
  costs of trade secret and patent litigation 123
  multiple regimes and 78
  precautions as substitute 67–8
  vs self-help 47–8
Lloyd Corp. Ltd v. Tanner 279
The law and theory of trade secrecy

lobbying 106
Lockean labor/desert 65–6
Loshin, J. 239
low level exposures 450–52
Lyndon, M.L. 253, 383
M&M’s 11–12
Machlup, F. 148
Madison, M.J. 226, 243
magicians 239–40
Maine lobster fishery 226
Mallinckrodt Inc. v. Medipart, Inc. 371
Mansfield, E. 209, 337
manufacturing, multi-stage 161
markets 225
non-competition covenants and 84
Mars, Forrest, Sr 11, 12
Mars Company 9–12, 15
Marwell, G. 217
mass market licenses 274
Material Transfer Agreements (MTAs) 526–8, 535
mathematical methods 169
Matsuo, K. 521
Matthews, B. 323
McClary v. Hubbard 51–2, 56
McDonald’s 178
McDonnell Douglas Corporation v. Widnall 430–31
medical biotechnology sector 258, 261
Medicare 384
Meihigan, S. 522
Mettiner, J. 578
membership, commons 227–9, 230–31
Merges, R.P. 150, 256
meta-analysis 487–8
methods/processes, secret 240–43, 250, 340–43
Mexico 9, 125, 156, 165, 549
Microsoft 231, 234, 242, 278, 360–62
European Microsoft case 360–62, 377
Michrotech International, Inc. v. Fair 395
military procurement 430–31
Milkar v. Taylor 321
Milppurruru & Ors v. Indofurn Pty Ltd & Ors 505–6
mines 203–4
misappropriation 31, 32–3, 112, 113, 133, 140–41
codified misappropriation laws 195
and commons governance 227–9, 231–3
direct misappropriators and First Amendment defenses 287–8
UTSA and common law 38–42
UTSA and the TRIPS Agreement 557–9
Mishina, K. 204
misleading information 515, 516
Mississippi State University (MSU) v. People for the Ethical Treatment of Animals (PETA) 426–8
mixed agreements 255, 265
Moby-S system 254
Moncrief, N. 391
monetary damages/relief 24–5, 439
monopolies 249, 335–6, 358–65
bad faith litigation 363–5
conduct of monopoly firms 375–9
refusal to supply 358–63, 375–6
monopoly rents, no extraordinary 157–9
Monsanto 281–2, 365, 461
morality/ethics 65–6, 585–6
commercial 120–21
competitive 519
morning star pole 504
Morocco 587
Morrison, P.D. 204–5
Morse, Representative 344
Mortgage Specialists, Inc. v. Davey 36
Moser, P. 168
Mountford, C.P. 511–13
Moynihan, D.P. 440
multifactor test 53–4
multiple regimes of confidentiality 77–108
confidentiality contracts 43–4, 80, 88–91, 99, 107, 127, 162, 252
non-competition covenants 83–7, 99, 107, 562–3
official trade secret law 81–3, 99
potential solutions 104–8
the problem 79–81
results of the confusion in trade secret law 98–101
sources of the problem 101–4
unofficial trade secret law
Index 603

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(confidentiality torts)</td>
<td>91–8, 99, 100, 108</td>
</tr>
<tr>
<td>multi-stage manufacturing</td>
<td>161</td>
</tr>
<tr>
<td>National Advertising Division (NAD)</td>
<td>384</td>
</tr>
<tr>
<td>of the Council of Better Business Bureaus</td>
<td></td>
</tr>
<tr>
<td>National Commission on New Technology Uses of Copyrighted Works (CONTU)</td>
<td>328</td>
</tr>
<tr>
<td>National Conference of Bar Examiners v. Multistate Legal Studies, Inc.</td>
<td>312, 313, 316, 319–20, 331</td>
</tr>
<tr>
<td>National Conference on Uniform State Laws 20–21, 248, 554</td>
<td></td>
</tr>
<tr>
<td>National Institutes of Health (NIH)</td>
<td>491</td>
</tr>
<tr>
<td>Recombinant DNA Advisory Committee (RAC)</td>
<td>479</td>
</tr>
<tr>
<td>National Parks Conservation Association v. Morton</td>
<td>463</td>
</tr>
<tr>
<td>national security</td>
<td>397</td>
</tr>
<tr>
<td>natural law</td>
<td>50</td>
</tr>
<tr>
<td>natural lead time</td>
<td>142, 189, 252</td>
</tr>
<tr>
<td>natural open-source technology pool</td>
<td>190–93</td>
</tr>
<tr>
<td>natural resource commons</td>
<td>225–6</td>
</tr>
<tr>
<td>Nebraska v. Kuhl</td>
<td>423–4</td>
</tr>
<tr>
<td>negative information</td>
<td>250, 487</td>
</tr>
<tr>
<td>negligence, contributory</td>
<td>69–70, 136</td>
</tr>
<tr>
<td>Nepal</td>
<td>583</td>
</tr>
<tr>
<td>Nestlé, H.</td>
<td>11</td>
</tr>
<tr>
<td>networks</td>
<td></td>
</tr>
<tr>
<td>among like-minded attorneys</td>
<td>105–6</td>
</tr>
<tr>
<td>network effects</td>
<td>213–14</td>
</tr>
<tr>
<td>New Drug Applications (NDAs)</td>
<td>467–91</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>36</td>
</tr>
<tr>
<td>new technology start-ups</td>
<td>100</td>
</tr>
<tr>
<td>New York Broadcast Employees</td>
<td></td>
</tr>
<tr>
<td>Freedom to Work Act</td>
<td>106</td>
</tr>
<tr>
<td>New York Times Co. v. United States</td>
<td></td>
</tr>
<tr>
<td>(Pentagon Papers case)</td>
<td>284, 290–92</td>
</tr>
<tr>
<td>Newman, N.</td>
<td>165</td>
</tr>
<tr>
<td>newsworthy secrets, third party recipients</td>
<td>288–95</td>
</tr>
<tr>
<td>non-competition covenants</td>
<td>83–7, 99, 107, 562–3</td>
</tr>
<tr>
<td>non-disclosure agreements</td>
<td></td>
</tr>
<tr>
<td>(confidentiality contracts)</td>
<td>43–4, 80, 88–91, 99, 107, 127, 162, 252</td>
</tr>
<tr>
<td>non-governmental organizations</td>
<td>(NGOs) 384, 401, 527</td>
</tr>
<tr>
<td>non-obviousness</td>
<td>166, 191, 194, 196, 198–9</td>
</tr>
<tr>
<td>non-profit sector</td>
<td>403</td>
</tr>
<tr>
<td>normative case for the RSP</td>
<td>48, 64–75</td>
</tr>
<tr>
<td>norms, social</td>
<td>238–40, 244–5</td>
</tr>
<tr>
<td>North American Free Trade Agreement (NAFTA)</td>
<td>501</td>
</tr>
<tr>
<td>North Carolina State Board of Elections (BOE)</td>
<td>419–21, 422, 423</td>
</tr>
<tr>
<td>notice 49–50, 59–60, 62–3</td>
<td></td>
</tr>
<tr>
<td>novelty 31–2, 166, 498–9</td>
<td></td>
</tr>
<tr>
<td>Nuvolari, A.</td>
<td>203–4, 213</td>
</tr>
<tr>
<td>Obama, B.</td>
<td>396, 406</td>
</tr>
<tr>
<td>obvious innovations</td>
<td>171–3</td>
</tr>
<tr>
<td>non-obviousness</td>
<td>166, 191, 194, 196, 198–9</td>
</tr>
<tr>
<td>Office of Management and Budget</td>
<td>406</td>
</tr>
<tr>
<td>O’Grady v. Superior Court</td>
<td>282</td>
</tr>
<tr>
<td>Oliver, P.E.</td>
<td>217</td>
</tr>
<tr>
<td>Oman</td>
<td>583</td>
</tr>
<tr>
<td>online advertising</td>
<td>392–3</td>
</tr>
<tr>
<td>online credit checking systems</td>
<td>208</td>
</tr>
<tr>
<td>open access</td>
<td>253</td>
</tr>
<tr>
<td>open biotechnology</td>
<td>235–7, 246–66</td>
</tr>
<tr>
<td>trade secrecy and 254–6</td>
<td></td>
</tr>
<tr>
<td>open code e-voting systems</td>
<td>400</td>
</tr>
<tr>
<td>Open Government Directive</td>
<td>472</td>
</tr>
<tr>
<td>open infrastructures</td>
<td>251–4</td>
</tr>
<tr>
<td>open innovation</td>
<td>201–21</td>
</tr>
<tr>
<td>evidence of open revealing</td>
<td>203–6</td>
</tr>
<tr>
<td>paradigm 265–6</td>
<td></td>
</tr>
<tr>
<td>positive incentives for open revealing</td>
<td>212–16</td>
</tr>
<tr>
<td>practical case for open revealing</td>
<td>206–16</td>
</tr>
<tr>
<td>private-collective model for innovation incentives</td>
<td>202, 216–21</td>
</tr>
<tr>
<td>open patent</td>
<td>253</td>
</tr>
<tr>
<td>open science</td>
<td>201</td>
</tr>
<tr>
<td>open source regimes</td>
<td>253, 262–3</td>
</tr>
<tr>
<td>biotechnology</td>
<td>235–7, 247, 263, 265</td>
</tr>
</tbody>
</table>

Rochelle C. Dreyfuss and Katherine J. Strandburg - 9780857933072
Downloaded from Elgar Online at 06/12/2019 07:33:46PM via free access
software 205, 206, 213, 214–16, 217–18, 219, 225
open-source technology pool 190–93, 194
open standard 214
openness
secrecy and 222–4
see also commons
optimal level of precaution 68–70
Oregon Steam Navigation Co. v. Winsor 340
O’Reilly, J.T. 484–5
originality 166
Ostrom, E. 225–6, 257
over-investment in secrecy 124–6, 129
ownership issues 502–10
Paepke, O. 187
Panama 587
Paris Convention 503
Article 10bis 141, 186, 514–16, 519, 521, 538, 548–9
Parker, A. 349
Pasquale, F. 242, 382, 394, 397, 398
Patent Act 44
patent citations 164–5
patent pools 225, 232, 247, 256, 257–8, 265
Patent, Trademark and Copyright (PTC) Section of the American Bar Association 554
patents 18, 47, 111, 190, 223, 236, 280–81, 460

candy industry and 12
channeling protection between trade secrets and 128–31
compatibility of trade secrecy and patent law 272–3
conflict with trade secret law and the TRIPS Agreement 564–5
disclosure 123–4, 471
and incentives 122–3, 147–8, 152–3, 158–9, 166–7, 167–74, 181
indigenous innovation and 530–34
low profits from patenting 209–12
new Italian regime and the patent system 143–50
non-obviousness 196
open patent 253
and openness 223, 236
regime choice 337–9
strength compared with trade secrecy 16–17
and transparency 410–11, 433, 435–6
Patterson, L.R. 321, 323
Peabody v. Norfolk 18, 342
Peerless Roll Leaf Co., Inc. v. Lange 52
Pennsylvania 35
Penrose, E. 148
Pentagon Papers case 284, 290–92
Peritz, R.J.R. 146–7
Perlman, H. 21
personal computers (PCs) 300–301
personhood theory 66
Peru 537, 563, 585, 587
‘Peruna’ 345–7
Peruvian Law of Protection of the Collective Knowledge of Indigenous Peoples 532–3
pesticides 448, 464–5
Peter Paul Candies 11
Peterson, J.R. 554
pharmaceutical industry 172, 261
test data exclusivity see test data exclusivity
Phillip Morris, Inc. v. Reilly 433–4, 461
Pilkington 354–6, 365, 374
Pitjantjatjara People 511–13
plant genetic resources 200
plant knowledge 526
plant variety protection laws 194, 195
policy
effects and incentives 159
objectives of confidentiality regimes 82, 85–7, 90–91, 97–8
political google-bombing 396–7
Pollan, M. 125–6
pollution
and information 446–9
see also environmental law
Pooley, J.H.A. 134
positive commons 256
Posner, R.A. 153
practice, learning through 174
precautions 24
as necessary to trade secret rights in all cases 50–52
as notice and as safeguard against publication 49–50
reasonable secrecy precautions see reasonable secrecy precautions (RSP) requirement
predictability in counseling 83
pre-emption 93–6
copyright 37–8, 301–2, 303–9
provision of the URTA 34–44, 93–6
trade secrets as IP rights and 133–5
and the TRIPS Agreement 563–5
preliminary injunctions 283–5, 286–7, 296
presumptions 366–9, 373, 380
pricing, lack of monopoly rents and 157–9
prior restraints doctrine 283–95
privacy rights 66
and incentives 179–81
private-collective model of innovation incentives 202, 216–21
private concern 293–4, 438
private investment model of innovation incentives 206, 216, 220
private sector–government relationship 407–9, 417–41
private provision of public infrastructure 417–18, 419–25, 434–6
public funded/sponsored research and contracts 418, 425–8, 491
process costs 67–70
processes/methods, secret 240–43, 250, 340–43
Procter & Gamble Co. v. Bankers Trust Co. 288–9, 290
product differentiation 158–9
profits 336
low profits from patenting 209–12
programmed obsolescence 147–8
Project Orinoco website 530, 531
‘Promoting Innovation’ report 332, 375
property rights 278, 279, 333–4
environmental law and trade secrecy 460–61
indigenous innovation and 503–4, 513–20
IP, property and ‘absolute dominion’ 137–8
precautions and common law 50–52
and trade secret theory 118–20
trade secrets are not property akin to patents, copyrights or land 279–81
trade secrets and the First Amendment defense 281–3
see also intellectual property
property theory
decline of 52–3
dominance (1860 to 1920) 49–52
prostratin 526–7
protection
hyper-protectionist legal environment 195–8
term see duration of protection
trade secret law vs no protection 154–65
public benefit 320–28
Public Citizen Health Research Group v. FDA 477–8, 479
public concern 293–4, 437–8
public contracting 430–31
public failure 400–401
public goods 202, 216–17
invention as a public good 155
Public Health Service Act 476–7
public infrastructure 411, 417–41
eliminating trade secrecy protection for 433–7
private provision of 417–18, 419–25, 434–6
public interest 281–2, 293–4
public libraries 225
public option 384, 398–402, 404–5
public transparency see transparency publication
copyright and 312–13, 324–6
precautions as safeguard against 49–50
Punte del Este Declaration 540
pure pooling equilibrium 74
Putnam, G. 314
qualified transparency 383, 466
quality, review of 368–9
quasi-contract 31, 32
Raymond, E.S. 213
Raytheon 363–4

Index 605

Rochelle C. Dreyfuss and Katherine J. Strandburg - 9780857933072
Downloaded from Elgar Online at 06/12/2019 07:33:46PM via free access
<table>
<thead>
<tr>
<th>Index</th>
<th>607</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rockett, K.</td>
<td>518</td>
</tr>
<tr>
<td><em>Rockwell Graphics Systems, Inc. v. DEV Industries, Inc.</em></td>
<td>59, 60</td>
</tr>
<tr>
<td><em>Rohm &amp; Haas Co. v. Adco Chemical Co.</em></td>
<td>132, 136</td>
</tr>
<tr>
<td>routine engineers</td>
<td>192–3, 194</td>
</tr>
<tr>
<td>routine innovation</td>
<td>191, 194</td>
</tr>
<tr>
<td>Rowntree</td>
<td>9</td>
</tr>
<tr>
<td>royalty collection clearinghouse</td>
<td>260–61</td>
</tr>
<tr>
<td><em>RTE Corp. v. Coatings, Inc.</em></td>
<td>60</td>
</tr>
<tr>
<td>Rubin, P.H.</td>
<td>86</td>
</tr>
<tr>
<td><em>Ruckelshaus v. Monsanto Co.</em></td>
<td>118–19, 279, 281–2, 461</td>
</tr>
<tr>
<td>rule of doubt</td>
<td>301</td>
</tr>
<tr>
<td>rule of reason analysis</td>
<td>369–70, 374–5, 379</td>
</tr>
<tr>
<td>rules</td>
<td></td>
</tr>
<tr>
<td>general rules and RSP requirement</td>
<td>70, 71–2, 73</td>
</tr>
<tr>
<td>liability rules see liability rules</td>
<td></td>
</tr>
<tr>
<td>Russia</td>
<td>583</td>
</tr>
<tr>
<td>sacred ceremonies</td>
<td>223, 495, 511</td>
</tr>
<tr>
<td><em>Salinger case</em></td>
<td>329–30</td>
</tr>
<tr>
<td>Samoan traditional healers</td>
<td>526–7</td>
</tr>
<tr>
<td>Samuelson, P.</td>
<td>141, 185, 252, 310</td>
</tr>
<tr>
<td>Sancho, I.</td>
<td>421</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>583</td>
</tr>
<tr>
<td>Savage, D.</td>
<td>391</td>
</tr>
<tr>
<td>scholarly attention</td>
<td>103, 104–5</td>
</tr>
<tr>
<td>Schulman, E.M.</td>
<td>86</td>
</tr>
<tr>
<td>Schwarzman, M.R.</td>
<td>442</td>
</tr>
<tr>
<td>science</td>
<td>217</td>
</tr>
<tr>
<td>commons</td>
<td>190–92, 193, 194</td>
</tr>
<tr>
<td>Scientology, Church of</td>
<td>523–4</td>
</tr>
<tr>
<td>scope of trade secret law</td>
<td>112–15</td>
</tr>
<tr>
<td>Scotchmer, S.</td>
<td>141, 185, 252</td>
</tr>
<tr>
<td>search engine optimizers (SEO)</td>
<td>382, 387–8, 389–91</td>
</tr>
<tr>
<td>search engine rankings/results</td>
<td>381–405</td>
</tr>
<tr>
<td>as a commons</td>
<td>240–43</td>
</tr>
<tr>
<td>public option</td>
<td>384, 398–402, 404–5</td>
</tr>
<tr>
<td>regulation agency expertise</td>
<td>383–4, 392–8, 404</td>
</tr>
<tr>
<td>secrecy and accountability</td>
<td>384–92</td>
</tr>
<tr>
<td>search software, library</td>
<td>204–5</td>
</tr>
<tr>
<td><em>Sears, Roebuck &amp; Co. v. Stifel Co.</em></td>
<td>135, 554</td>
</tr>
<tr>
<td>Second Enclosure Movement</td>
<td>194</td>
</tr>
<tr>
<td>secondary liability rule</td>
<td>273</td>
</tr>
<tr>
<td>secrecy requirement</td>
<td>112, 167, 554–6</td>
</tr>
<tr>
<td>centrality of</td>
<td>131–3</td>
</tr>
<tr>
<td>channeling protection between patents and trade secrets</td>
<td>128–31</td>
</tr>
<tr>
<td>secret copyrights</td>
<td>302–3</td>
</tr>
<tr>
<td>impetus for</td>
<td>310–12</td>
</tr>
<tr>
<td>see also copyright</td>
<td></td>
</tr>
<tr>
<td>secret formulas/recipes</td>
<td>9, 10, 11, 13, 178–9, 238–9, 343–50, 416</td>
</tr>
<tr>
<td>secret methods/processes</td>
<td>240–43, 250, 340–43</td>
</tr>
<tr>
<td>secure tests</td>
<td>300, 310–12</td>
</tr>
<tr>
<td>deposit requirement</td>
<td>312–20</td>
</tr>
<tr>
<td>selective incentives</td>
<td>217</td>
</tr>
<tr>
<td>self-determination</td>
<td>506, 509</td>
</tr>
<tr>
<td><em>Self Directed Placement Corp. v. Control Data Corp.</em></td>
<td>28</td>
</tr>
<tr>
<td>self-help</td>
<td>249, 251</td>
</tr>
<tr>
<td>discouragement of costly and wasteful investment in</td>
<td>64–5</td>
</tr>
<tr>
<td>inherent secrecy incentives</td>
<td>155–63</td>
</tr>
<tr>
<td>vs litigation</td>
<td>47–8</td>
</tr>
<tr>
<td>see also reasonable secrecy precautions (RSP) requirement</td>
<td></td>
</tr>
<tr>
<td>self-revealing know-how</td>
<td>194, 195–8</td>
</tr>
<tr>
<td>semicommons</td>
<td>191, 192–3, 194</td>
</tr>
<tr>
<td>Semiconductor Chip Protection Act (1984)</td>
<td>199</td>
</tr>
<tr>
<td>semiconductor manufacture</td>
<td>204</td>
</tr>
<tr>
<td>Shah, S.</td>
<td>205, 211</td>
</tr>
<tr>
<td>shared information, value of</td>
<td>155, 163–5</td>
</tr>
<tr>
<td>Shedd, P.</td>
<td>86</td>
</tr>
<tr>
<td>Sherman Act (1890)</td>
<td>339, 344–50, 351</td>
</tr>
<tr>
<td>Sherwood, R.M.</td>
<td>125, 156, 165</td>
</tr>
<tr>
<td>‘side letters’</td>
<td>587–8</td>
</tr>
<tr>
<td>signaling</td>
<td>72–5</td>
</tr>
<tr>
<td><em>Sikes v. McGraw-Edison Co.</em></td>
<td>30</td>
</tr>
<tr>
<td>Silberston, Z.A.</td>
<td>211</td>
</tr>
<tr>
<td>Silicon Valley</td>
<td>83, 164, 234, 408</td>
</tr>
<tr>
<td>similar/identical information</td>
<td>166, 207–9</td>
</tr>
<tr>
<td>Singleton, S.</td>
<td>217</td>
</tr>
<tr>
<td>Skin Deep</td>
<td>449</td>
</tr>
<tr>
<td>Skor bar</td>
<td>11</td>
</tr>
<tr>
<td>Slashdot</td>
<td>401</td>
</tr>
<tr>
<td>small and medium enterprises</td>
<td>149–50</td>
</tr>
<tr>
<td>small-scale innovation</td>
<td>194, 195–8, 198–200</td>
</tr>
<tr>
<td><em>Smith v. Dravo Corp.</em></td>
<td>114, 132</td>
</tr>
</tbody>
</table>
social norms 238–40, 244–5
software 158, 176–7, 212, 299–300,
300–31, 310–12, 322
open source 205, 206, 213, 214–16,
217–18, 219, 225
source code 310–11, 312
of breathalyzer machines 423–5
South Korea 580–81
Southwest Research Institute v.
Keraplast Technologies, Ltd. 297
Spain 9
special master 383
spillovers 227, 231, 241–2, 244
spiritual value 522–4
sports innovations 205
Sports Management News (SMN) 289
spying/espionage 9, 11, 80
Standard Material Transfer Agreement 528
standardized licenses clearinghouse 260–61
start-ups 100
state courts 102
alternative torts 92–7
crowded dockets 102
State ex rel. Sports Management News,
Inc. v. Nachtigal 289
state law 18, 81–3, 302, 334
statutory law 21–2
steam engines 203–4
Stedman, J.C. 187
Steinemann, A.C. 449
Sterk, S.E. 86
storage space 313–14
Strandburg, K.J. 226, 239
strict liability torts 559–60
substantial secrecy 555
substitute information/knowledge 166,
207–9
summary information 475, 479, 485
Sun Microsystems 360–62, 377
Supremacy Clause 38, 97, 98, 100,
135
Supreme Court, U.S. 16, 38
Switzerland 187, 550–51, 565
synoptic tables 548

Tabor v. Hoffman 50
tacit know-how 169–70
tangibility 556–7
taubman, A. 573–4
tax preparation software 158
TaxCut 158
Taylor, C.T. 211
Taylor, M. 217
Taylor v. Blanchard 341, 343
technical drawings and specifications 300
technological change 443
technology exchange clearinghouse 259–60
technology pool, open-source 190–93,
194
technology transfer 148
telecommunications spectrum allocation 242–3
telephone calls, illegal interception of 292–4
temporary restraining orders (TROs) 288–9
Terarecon, Inc. v. Fovia, Inc. 35–6
term limit on secrecy protection 138
territorial homelands 506–7, 509
territorial restraints 352–6, 372–5
test data exclusivity 288–9
international trade secrecy protection 549, 552, 568–90
Article 39(3) of the TRIPS Agreement 565–6, 568–82,
589
effects of TRIPS-plus standards 584–8, 589
FTAs and WTO accession 582–3
regulatory exclusivity in the U.S. 467–91
accelerating the time of disclosure 486–91
Hatch-Waxman Act 467–8, 469,
480–86, 488
origins of current administrative practice 473–80
Texaco, Inc. v. Dagher 370
Thailand 586
theft 39
third party liability 559–60
third party recipients of newsworthy
secrets 288–95
Tirole, J. 213
Tobler, J. 11
torts 112, 334
confidentiality torts 91–8, 99, 100, 108
environmental law 456–7
relationship between trade secret law and other torts 133–5
strict liability torts 559–60
tort law and trade secret theory 115–18
see also common law
Toxic Substances Control Act (TSCA) 444, 453–4
trade secret doctrine 111–15, 409–17
history of trade secret law 111–12
scope of trade secret law 112–15
trade secret theory 115–21
commercial morality 120–21
contract law 118
property law 118–20
tort law 115–18
Trade Secrets Act (TSA) see Economic Espionage Act
trademarks 18, 47, 111
and incentives 166–7, 178–9
traditional cultural expressions 496–7
see also indigenous innovation
traditional healing 510, 522, 526–7
traditional knowledge see indigenous innovation
Traditional Knowledge (TK) Digital Library 530, 531, 532
training, employee 86–7
transparency 406–41, 462
impact of trade secrecy on 417–32
potential solutions and future research 432–40
private provision of public infrastructure 417–18, 419–25, 434–6
public funded/sponsored research and contracts 418, 425–8
qualified 383, 466
trade secrecy doctrine 409–17
trade secrecy exception to FOIA 428–32
Transparency Initiative 472
trespass 68, 112
Trevithick, R. 204
TRIPS Agreement (Agreement on Trade-Related Aspects of Intellectual Property Rights)
146–7, 151, 248, 334, 486
Article 39 see Article 39 of the TRIPS Agreement
Article 40 563
Article 41 529
Article 44 562
indigenous innovation 498–9, 500, 536
negotiations 517–18, 568–9
TRIPS-plus standards 584–8, 589
trust 264
trusted institutions 383–4, 392–8, 466
Tunisia 580
TurboTax 158
Twentieth Century Music Corp. v. Aiken 322
2bigfeet.com 391
tyling 356–8
unauthorized access 112
uncertified patents 150
uncopyrightable information 175
unfair competition 38, 40, 112, 117–18, 133, 135
Article 39 of the TRIPS Agreement 514–20, 546–7, 548, 575
history of U.S. trade secret law 52–6, 553–4
dominance (1940 to 1980) 55–6
rise of 52–4
indigenous innovation 513–20
Restatement (Third) of 21–33, 40, 45, 57, 62, 280, 334, 413, 415, 458–9
Italian reform 140–41, 143, 151
Uniform Trade Secrets Act (UTSA) 20–21, 44, 92, 97, 112, 131, 137, 178, 180, 247, 248
and Article 39 of the TRIPS Agreement 186, 537–9, 552–67
impact of pre-emption principles 563–5
limitations reflected in the language of Article 39 554–60
and confidentiality contracts 91
definition of a trade secret 25–8, 57, 227–8, 250, 334, 414–15, 521
displacing common law 33–44
multiple regimes of confidentiality 81–3
ownership 505
pre-emption provision 33–44, 93–6
Restatement (Third) of Unfair Competition and 21–33
RSP requirement 14–15, 46–76
uniqueness 166, 498–9
United Kingdom (U.K.) 522
British Statute of Anne 320
Commission on Intellectual Property Rights (CIPR) 578
United Nations Institute of Advanced Studies (UNU-IAS) 534
United Nations Special Rapporteur on the right to health 578
United States (U.S.) 164, 196, 248, 568
complaint against Argentina 573
Federal Trade Commission (FTC) 360, 383, 392–3
Food and Drug Administration see Food and Drug Administration (FDA)
FTAs 582, 587–8
Government Accountability Office (GAO) 454, 570, 588
history of trade secret law 49–58, 553–4
dominance of property theory 49–52
focus on reasonable precautions 57–8
rise and dominance of unfair competition 52–6
Office of Management and Budget 406
Restatements see Restatements
status of trade secret law 18–45
test data exclusivity 467–91
TRIPS Agreement negotiations 537, 539–41, 541–2, 545, 546–7, 548, 550–51, 551, 561, 564–5, 568–9
Unfair Trade Secrets Act see Unfair Trade Secrets Act (UTSA)
United States v. Addyston Pipe Co. 347
United States Air Force (USAF) 430–31
United States v. Arnold, Schwinn & Co. 352
United States v. Gen. Motors Corp. 351
United States v. Loew’s, Inc. 356
United States v. Pilkington PLC 354–6, 374
United States Sporting Products, Inc. v. Johnny Stewart Game Calls, Inc. 132
United States Trade Representative (USTR) 570, 582
Special 301 Reports 572
United Steelworkers of Am. v. Auchter 461
Universal Declaration of Human Rights (UDHR) 507
unjust enrichment 38, 40, 65–6, 112, 133
unpatentable subject matter 169–71
unpublished works 323–6, 328–30
Uruguay Round 539, 551–2, 568–9
use or disclosure 23
use rights 503, 506–9
usefulness 166–7
user-developed innovations 215
USM Corp. v. Marson Fastener Corp. 29
utility model laws 191, 194, 195, 196
Vaidhyanathan, S. 400–401
Verizon Commns Inc. v. Law Offices of Curtis V. Trinko 358
vertical resale price agreements 347–50, 350, 351
Viacom v. YouTube 394–5
Vickery v. Welch 18, 340
Vienna Convention on the Law of Treaties 574–5, 589
virtual teams 219
Visscher, F. de 249
Volokh, E. 282, 437
Von Hippel, E. 204–5, 208–9, 234, 238–9
Von Krogh, G. 214, 234
Voth, H.R. 495, 506, 511
voting machines 382, 399, 419–23, 425
Wark, M. 403
Warren, S.D. 179–80
Washington Post 273
Washingtonian Publishing Co. v. Pearson 316–18
Watt, J. 204
websites 530–31, 535
Wechsler, H. 22
Weissman, R. 580
Weizner, D. 393
welfare 244
‘whistle-blowing’ statutes 274
white hat SEO 387–8, 389–91
White Motor Co. v. United States 352
wholesale duplication 190
Wiesner, D. 120–21
Wikipedia 401, 499
Wilf, S. 458
Wilson, M.P. 442
wiretap law 292–3
Wisconsin 34, 95

‘Wistar’s Balsam of Wild Cherry’
343–4, 350, 373, 374
work for hire doctrine 506
World Health Organization (WHO) 577
World Intellectual Property Organization (WIPO) 531, 541
Intergovernmental Committee (IGC) 496–7, 507
World Trade Organization (WTO) 573
accession to 582–3
wrongful means see improper means

xenotransplantation 479–80

Yahoo 386
Yeadon, M. 522
Young, F. 484
Yu, P. 508
Zimmerman, R. 10